DEC 11, 2015 7:28 AM PST

Triple microRNA Helix Shrinks Aggressive Tumors

WRITTEN BY: Xuan Pham
Since their discovery in the early 1990s and 2000s, micro RNAs (miRNAs) have been implicated in a variety of human conditions, including cancer. But scientists also suspected that modulating the levels of certain miRNA could have therapeutic effects against cancer growth. The real challenge was a lack of efficient delivery system that could release miRNAs to targeted tumor cells. Researchers at Massachusetts Institute of Technology may have solved this problem, and in the process, shrank tumors by 90%.
 
An adhesive hydrogel containing triple twisted microRNAs shrinks cancer in mice.

Micro RNAs (miRNAs) are simply short nucleotide sequences, usually 21-23 bases long, and act to silence gene expression. In some human cancers, certain miRNAs are either too overactive or underactive, which leads to cancer genes to be erroneously expressed. In this study, the research team focused on 2 naturally occurring miRNAs: miR-205, which is frequently silenced in cancer cells; and miR-221, which is often overactive in cancer cells.
 

Because traditional miRNA delivery methods have been inefficient, the team created their own system, which consisted of three miRNA sequences that self-assembled into a triple helix. Each of the three miRNA sequences had unique functions: one sequence mimicked the actions of miR-205 to silence cancer cells; one sequence blocked the activity of miR-221; and the last sequence added stability to the triple helix.

The triple twists of the miRNAs proved to be a more stable structure than single or double RNA strands. The team then added two previously developed polymers, dextran and dendrimer, to create an adhesive hydrogel that protected the RNA triple helix. This hydrogel concoction is also injectable, which further aided delivery of the miRNA to targeted tumor sites.

Upon tumor contact, the miRNA-dendrimer nanoparticles get released and absorbed into tumor cells. The triple helix then gets dissociated into the three miRNA sequences. Each miRNA acts separately but synergistically to kill the tumor.

To test their miRNA delivery platform, the scientists injected the gel into mice with triple-negative breast tumors. These mice represent the most intractable form of breast cancer, as they lack all three common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. In these mice, the triple helix treatment shrank tumors by 90% while increasing survival rate from 7 days to 75 days. These results were far superior to other treatments that included injection of the same miRNAs in single and double strand form.

The dramatic and successful shrinkage of the mouse tumor is great proof of principle for the method of triple helix miRNA delivery. With one injection, the researchers were able to turn on a tumor-suppressing miRNA while snuffing out the one that causes cancer. Additionally, the structures are highly stable and easily targeted to cancer cells. The researchers are now looking to further expand the applications of their triple RNA helix method. Conceivably, this method could be adapted to treat other types of solid tumors, and deliver different types of RNA, DNA or other therapeutic agents.

Sources: Nature Materials, MIT News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 21, 2020
Clinical & Molecular DX
Fidget Spinner Diagnoses Infections
MAY 21, 2020
Fidget Spinner Diagnoses Infections
The fidget spinner toy craze took the world by storm — a small, boomerang-shaped gadget that rotates hypnotically ...
JUN 26, 2020
Cardiology
Drug for Osteoporosis Linked to Increased Risk of Adverse Cardiovascular Events
JUN 26, 2020
Drug for Osteoporosis Linked to Increased Risk of Adverse Cardiovascular Events
In a recent study done by Jonas Bovijn, MBChB, MSc, DLSHTM, of the Big Data Institute at the University of Oxford’ ...
JUL 27, 2020
Clinical & Molecular DX
Guidance for Optimization of a Real-Time qPCR Assay
JUL 27, 2020
Guidance for Optimization of a Real-Time qPCR Assay
Optimizing the formulation of reagents for your qPCR assay requires careful experimental design that looks across severa ...
AUG 18, 2020
Clinical & Molecular DX
DIY COVID Tests Instead of Vaccines?
AUG 18, 2020
DIY COVID Tests Instead of Vaccines?
Routine, do-it-yourself COVID-19 testing could be just as good as a vaccine when it comes to stopping the transmission o ...
SEP 17, 2020
Coronavirus
A Biomarker May Predict the Most Severe COVID-19 Cases
SEP 17, 2020
A Biomarker May Predict the Most Severe COVID-19 Cases
Researchers may have found a way to identify the COVID-19 patients that will need targeted therapies the most.
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
Loading Comments...